Talis Biomedical Corporation (TLIS)
USD 1.84
(3.37%)
USD 1.84
(3.37%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -53.24 Million | -100.13 Million | -171.38 Million | -87.02 Million | -24.32 Million | -20.94 Million |
| Net Income | -62 Million | -113.01 Million | -192.03 Million | -91.13 Million | -27.47 Million | -21.33 Million |
| Depreciation & Amortization | 5.07 Million | 8.83 Million | 1.57 Million | 763 Thousand | 726 Thousand | 647 Thousand |
| Deferred income taxes | 2.17 Million | - | - | - | - | - |
| Stock-based compensation | 4.35 Million | 5.36 Million | 9.2 Million | 3.68 Million | 965 Thousand | 679 Thousand |
| Change in working capital | -3.42 Million | -7.68 Million | 8.82 Million | -951 Thousand | 640 Thousand | -932 Thousand |
| Other non-cash items | 596 Thousand | 6.36 Million | 1.04 Million | 611 Thousand | 817 Thousand | 3.37 Million |
| Investing Cash Flow | -486 Thousand | -1.61 Million | -2.86 Million | -8.2 Million | -578 Thousand | -533 Thousand |
| Investments in PPE | -486 Thousand | -1.61 Million | -2.86 Million | -8.2 Million | -578 Thousand | -533 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 33 Thousand | 406 Thousand | 234.42 Million | 246.75 Million | 39.61 Million | 8000.00 |
| Debt repayment | - | - | - | - | -15 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 33 Thousand | 406 Thousand | 232.54 Million | 248.18 Million | 39.61 Million | 8000.00 |
| Other Financing Activities | 33 Thousand | 406 Thousand | 1.88 Million | -1.43 Million | - | 8000.00 |
| Accounts receivables | 259 Thousand | -125 Thousand | 288 Thousand | -238 Thousand | 192 Thousand | -1.99 Million |
| Accounts payables | -2.42 Million | -1.19 Million | 216 Thousand | 3.2 Million | 185 Thousand | 599 Thousand |
| Inventory | - | - | -288 Thousand | -4 Million | -192 Thousand | - |
| Other working capital | -1.25 Million | -6.36 Million | 8.6 Million | 91 Thousand | 455 Thousand | -1.53 Million |
| Cash at beginning of period | 130.19 Million | 233.31 Million | 173.13 Million | 21.6 Million | 6.89 Million | 28.36 Million |
| Cash at end of period | 76.73 Million | 131.96 Million | 233.31 Million | 173.13 Million | 21.6 Million | 6.89 Million |
| Capital Expenditure | -486 Thousand | -1.61 Million | -2.86 Million | -8.2 Million | -578 Thousand | -533 Thousand |
| Effect of forex changes on cash | 234 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | -53.45 Million | -101.34 Million | 60.17 Million | 151.52 Million | 14.7 Million | -21.46 Million |
| Free Cash Flow | -53.72 Million | -101.75 Million | -174.25 Million | -95.22 Million | -24.9 Million | -21.47 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.84 Million | -13.03 Million | -62 Million | -13.46 Million | -15.68 Million | -15.03 Million |
| Depreciation & Amortization | 84 Thousand | 262 Thousand | 5.07 Million | 614 Thousand | 217 Thousand | 168 Thousand |
| Deferred income taxes | - | - | 2.17 Million | -3.65 Million | 2.76 Million | - |
| Stock-based compensation | 791 Thousand | 601 Thousand | 4.35 Million | 1.02 Million | 1.07 Million | 1.07 Million |
| Change in working capital | -4.63 Million | 371 Thousand | -3.42 Million | 469 Thousand | 42 Thousand | -3.15 Million |
| Other non-cash items | 2.06 Million | 4.17 Million | 596 Thousand | 3.65 Million | 441 Thousand | 2.67 Million |
| Investing Cash Flow | 84 Thousand | 30 Thousand | -486 Thousand | 93 Thousand | -70 Thousand | -485 Thousand |
| Investments in PPE | - | - | -486 Thousand | 93 Thousand | -70 Thousand | -485 Thousand |
| Acquisitions | 84 Thousand | 30 Thousand | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 84 Thousand | 30 Thousand | - | - | - | - |
| Financing Cash Flow | - | 2000.00 | 33 Thousand | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 2000.00 | 33 Thousand | -33 Thousand | - | - |
| Other Financing Activities | - | 2000.00 | 33 Thousand | 33 Thousand | - | - |
| Accounts receivables | 7000.00 | 43 Thousand | 259 Thousand | -45 Thousand | 528 Thousand | -406 Thousand |
| Accounts payables | 171 Thousand | 2.28 Million | -2.42 Million | -1.35 Million | 236 Thousand | -1.15 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -4.81 Million | -1.95 Million | -1.25 Million | 1.87 Million | -722 Thousand | -1.59 Million |
| Cash at beginning of period | 70.33 Million | 76.73 Million | 130.19 Million | 87.99 Million | 100.75 Million | 115.51 Million |
| Cash at end of period | 59.86 Million | 70.33 Million | 76.73 Million | 76.73 Million | 89.53 Million | 100.75 Million |
| Capital Expenditure | - | - | -486 Thousand | 93 Thousand | -70 Thousand | -485 Thousand |
| Effect of forex changes on cash | - | - | 234 Thousand | - | - | - |
| Net cash flow / Change in cash | -10.47 Million | -6.39 Million | -53.45 Million | -11.26 Million | -11.21 Million | -14.75 Million |
| Free Cash Flow | -11.33 Million | -6.42 Million | -53.72 Million | -11.26 Million | -11.21 Million | -14.75 Million |
9969
0623
102940
STECF
2904
HBFG